1 0 7 a n a ly s i s
Lynch syndrome 1 have a substantially increased risk of colorectal and endometrial cancers, along with increased risk of ovarian, gastric, small bowel, urothelial, brain, hepatobiliary, pancreatic, bladder, kidney, prostate and breast cancers [1] [2] [3] [4] [5] [6] [7] [8] . However, intensive management reduces mortality 9 .
Sequence variants of uncertain functional and clinical relevance are common in genetic test reports. Although several lines of evidence can be evaluated to assess the clinical implications of these variants, usually none of these approaches can be used on its own to obtain clinically useful interpretations and, for many variants, comprehensive data are lacking. Laboratories are generally conservative in designating pathogenic variants, defining variants as being of 'uncertain significance' unless overwhelming evidence of pathogenicity exists. Several schemes for the classification of variants in genes associated with mendelian conditions have been proposed for use in the clinical setting. Because clinically useful actions are currently only considered for high-penetrance mutations, all of these systems are aimed at differentiating high-penetrance from low-penetrance and neutral variants and do not consider variants of intermediate risk. These schemes differ in the range and format of data used for classification and in the number of variant classes [10] [11] [12] . The International Agency for Research on Cancer (IARC) classification system, endorsed by the Human Variome Project (HVP), facilitates standardized categorization by defining classes that can be linked to validated quantitative measures of causality and/or pathogenicity from statistical models [13] [14] [15] [16] or to validated interpretation of qualitative data 17 . Importantly, only the five-class IARC system has been linked to clinical recommendations for all classes, including clinical testing and full high-risk surveillance guidelines for class 5 (pathogenic) and class 4 (likely pathogenic) variants; advice to treat as if "no mutation associated with disease has been detected" for class 1 (not pathogenic) and class 2 (likely not pathogenic) variants; and Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database a n a ly s i s acquisition of additional data to provide more robust classification for class 2 (likely not pathogenic), class 3 (uncertain) and class 4 (likely pathogenic) variants.
Locus-specific databases (LSDBs) are an important source of information for clinicians and researchers in assessing data and forming opinions on the clinical relevance of disease-associated gene sequence variants, and these databases have a fundamental role in variant classification owing to their added value from having aggregated data. Consistent and normalized data curation is critical to the value derived from databases in categorizing the relationship between genetic variation and disease-especially for clinical applications. It has previously been recommended by the IARC Working Group that a panel covering a range of expertise in variant classification provide consensus opinion on variant pathogenicity before publicly accessible display of such information 18 . Another important component of the classifications provided by LSDBs is transparency regarding the criteria and supporting information used for classification, which allows LSDB users to consider the information for their own applications in research or clinical settings 18 .
InSiGHT has merged multiple gene mutation and variant repositories to create the InSiGHT Colon Cancer Gene Variant Database for MMR and other colon cancer susceptibility genes [19] [20] [21] [22] [23] , hosted by the Leiden Open Variation Database (LOVD). Following recommendations for LSDB curation 18 , InSiGHT formed an international panel of researchers and clinicians to review MMR gene variants submitted to the database. To encourage the submission of unpublished clinical and research data to further facilitate variant classification, the microattribution approach 24 was implemented using Open Researcher and Contributor Identification (ORCID). Here we present the results of the InSiGHT Variant Interpretation Committee (VIC) effort to develop, test and apply a 5-tiered scheme to classify 2,360 unique constitutional MMR gene variants.
RESULTS

Curation of MMR gene variants
As of the end of December 2012, after 3,458 alterations to standardize nomenclature had been made, there were 12,635 submissions of 2,730 unique MMR gene variants lodged in the InSiGHT database. Furthermore, 370 unique variants (13.6%) were not identified in constitutional (germline) DNA (see Supplementary Fig. 1 and Supplementary Table 1 for details) and were excluded from further analyses because (i) no evidence existed that these occurred as constitutional variants and (ii) no clinical information was available to assess their potential roles in hereditary disease. The 2,360 constitutional variants included 932 MLH1 (39%), 842 MSH2 (36%), 449 MSH6 (19%) and 137 PMS2 (6%) variants. Most variants (800; 34%) were nonsense or frameshift changes predicted to cause protein truncation, with the next largest group (746; 32%) consisting of nonsynonymous variants that were not obviously truncating, including missense substitutions, small in-frame insertion-deletion mutations (indels) and read-through alterations of the translation termination codon.
Variants had originally been assigned a classification by submitters according to the following classes: pathogenic, probably pathogenic, no known pathogenicity, probably no pathogenicity or effect unknown. No information was recorded to document the rationale for classification or the standards used to classify variants. When considering the 1,382 constitutional variants with multiple entries in the InSiGHT database, discordance in classification between submitters was found for 869 variants. Some of this discordance arose because of classification based on single data points or references, such as results from a single functional assay 22 or inferences from individual publications originally lodged in the Mismatch Repair Genes Variant Database 23 (see the example in Supplementary Table 2) .
Development of a five-tiered system for classification
The InSiGHT VIC (Online Methods) was established in 2007 to address discrepancies in the classification of MMR gene variants lodged in the InSiGHT database. Since March 2011, the VIC has made a concerted effort to develop standardized criteria for variant classification, employing a modified Delphi consensus process 25 to evaluate current scientific evidence and reach consensus. In line with HVP 26 , the IARC classification system 10 for variant categorization ( Table 1 ) was adopted by InSiGHT for the classification of MMR gene variants. Briefly, multiple lines of evidence were required for classification, and evidence for each variant had to include data associating the variant with both clinical and functional consequences (Online Methods).
The scheme was first tested on a subset of 117 MMR gene variants, and the criteria evolved and were refined by consensus to accommodate new data and inconsistencies over multiple classification teleconferences and face-to-face meetings. Final criteria were then applied retrospectively and to all remaining unique variants listed in the database (Supplementary Table 3 ). An overview of the InSiGHT classification criteria is shown in Figure 1 (see Supplementary Table 4 and the Supplementary Note for detailed criteria and justifications). At the close of each VIC teleconference or meeting, consensus classifications were noted. Where necessary, action items to improve or clarify classification included (i) calls for missing clinical and functional information for specific variants to committee members and the general InSiGHT membership; (ii) requests for more detailed data or data clarification from the authors of original publications; and (iii) reassessment of classification after additional data were obtained. At the end of the process, the InSiGHT database was updated with the a n a ly s i s final consensus classifications and the supporting data to ensure transparency. The major issues faced by the committee in the review process included redundancy across multiple sources (resolved through discussion with the authors of original publications), paucity of information, incomplete or inaccurate data and difficulties in the interpretation of the results of functional assays. To facilitate the interpretation of findings from functional assays, supporting information and flowcharts were developed ( Fig. 1b and Supplementary Tables 5 and 6), and multiple meetings were coordinated that were dedicated to the review of variants with apparently discordant results from functional assays (Supplementary Table 3 ).
Validation of the InSiGHT qualitative classification criteria
Nonsense or frameshift alterations or large genomic deletions interrupting functionally important domains are generally considered pathogenic on the basis of DNA sequence alone; these variants were designated here as class 5a (assumed pathogenic). There were 990 assumed pathogenic variants in the database, 640 of which were private mutations. To demonstrate the robustness of the qualitative classification criteria, 170 assumed pathogenic variants (68 MLH1, 75 MSH2, 13 MSH6 and 14 PMS2) were reviewed as a validation set against the class 5 (pathogenic) qualitative criteria required for the assignment of variants to class 5b (Online Methods and Supplementary Table 7) . Designation of a variant as class 5b required evidence of abrogated protein function, at least two tumors with microsatellite instability (MSI) or appropriate loss of MMR protein expression and a segregation likelihood ratio of >10:1 (incorporating gene-specific cumulative risks 27 ) or variant cosegregation with disease reported in at least two Amsterdam criteria-positive families. Class 5b was attained by all 60 validation set variants that had sufficient clinical data to assess these required criteria. The other 110 validation set variants could not be assigned to class 5b, largely because family cosegregation and tumor data were scarce or unobtainable-presumably because these variants are accepted as disease causing and are routinely used for clinical presymptomatic testing in families (Online Methods). Of these variants, 72 were assigned to class 4 owing to lack of only 1 point of evidence, and 38 variants were assigned to class 3 owing to insufficient data. However, only 2 of 13 MSH6 and 2 of 14 PMS2 variants fulfilled class 5b criteria, reflecting the lower penetrance and later age of onset associated with deleterious variants in PMS2 (ref. 28) 29) . Together, these results indicate that the criteria for classification using qualitative data were sufficiently stringent to ensure conservative classification.
Classification of 2,360 constitutional MMR gene variants
Of the 12,006 eligible variant entries in the InSIGHT database, submitter and final classifications differed for 7,935 (66%), including changes from class 1 (not pathogenic) to class 5 (pathogenic) and vice versa (Fig. 2a) . The overall breakdown of final classifications is shown in Figure 2b . In addition to the 990 assumed pathogenic truncating or large-deletion variants (class 5a), consistent medical management is now also possible for the remaining 1,370 not obviously truncating variants; these include 167 class 5 (pathogenic) variants (class 5b) (12%), 183 class 4 (likely pathogenic) variants (14%), 86 class 2 (likely not pathogenic) variants (6%) and 169 class 1 (not pathogenic) variants (12%). Nonsynonymous variants made up the majority of class 3 variants (524/765; 68%) and newly assigned class 5b variants (91/167; 54%) ( Fig. 3  and Supplementary Fig. 2 ; see Supplementary Table 8 for detailed information supporting classifications). Substitutions at canonical dinucleotide splice sites fell predominantly in class 4 owing to lack of functional RNA analyses; however, if experimentally tested, these variants would likely be moved to class 5b. Intronic variants outside of conserved splice sites were the most prevalent variant type in class 1.
Final categorization (Online Methods) of not obviously truncating variants as class 1, 2, 4 or 5 was achieved by applying qualitative criteria for 391 variants, quantitative multifactorial likelihood analysis methodology (based on bioinformatic prior probabilities and evidence from segregation and/or tumor data; see Thompson et al. 16 ) for 192 variants and either quantitative or qualitative criteria for 26 variants. Where classifications derived using quantitative criteria differed from those generated with qualitative criteria, this difference reflected the amount of data available rather than deficiencies in the classification criteria, with no variants considered to fall into class 1 or 2 using one approach and class 4 or 5 using the other. Six synonymous variants were categorized in class 5b owing to their effects on splicing. Of the substitutions occurring in initiation codons (often assumed to be pathogenic [30] [31] [32] ), only one of nine had sufficient evidence to determine pathogenicity.
Implementing microattribution
Microattribution is a means to incentivize the placement of unpublished data in the public domain by assigning scholarly contribution to authors similar to the citation conventions afforded to journal LGDel PTC Figure 3 Classifications of all documented unique variants by variant type. The plot represents the proportion of the different variant types within the five classes. Class 5a is a subset of class 5 containing assumed pathogenic mutations (nonsense mutations, small frameshift indels and large deletions). All other variants placed in class 5 are termed class 5b variants (supplementary note). The different variant types include the following: ATG/UTR, variants in the initiation codon and the 5′ or 3′ UTR; I, intronic variants outside of the canonical splice-site dinucleotides; S, synonymous variants; NS, not obviously truncating nonsynonymous variants outside of the Kozak consensus sequence, i.e., missense, small in-frame indel and read-through translation termination codon alterations; SS, variants in the canonical splice-site dinucleotides;
LGDup, large genomic duplications;
LGDel, large genomic deletions or disrupting inversions; PTC, variants that introduce premature termination codons, i.e., nonsense mutations and small frameshift indels. See supplementary Figure 2 for further details of variant types by MMR gene. npg a n a ly s i s articles 33 . Retrospective and prospective microattribution was implemented to acknowledge and encourage the submission of unpublished data to the InSiGHT database, including the submission of additional detailed clinical information from authors of published reports. Microattribution was assigned for initial variant submission, segregation and family history data, pathology diagnostics (MSI analysis and immunohistochemistry) information, data from in vitro functional assays (mainly RNA splicing) and the determination of variant frequencies in normal individuals. As of July 2013, a total of 6,015 microattributions were conferred, including 3,763 for variant submission, 2,111 for family and tumor pathology data, 97 for data from in vitro assays and 25 for frequency data. Notably, 19% of the microattributions for clinical and functional data contributed additional information critical for the classification of variants in the class 5a (assumed pathogenic) validation subset. These data also highlighted the fact that clinical testing for these assumed pathogenic variants is mostly undertaken in the presymptomatic setting. The contribution of microattribution to the final classification of not obviously truncating variants is shown in Figure 4 . Notably, classification was altered for 57 of 169 (34%) variants for which unpublished data were obtained. Moreover, implementation of microattribution stimulated the submission of 128 new MMR gene variants yet to be classified. 34 were used to estimate the prior probability of pathogenicity for all 481 class 3 (uncertain) missense variants (Fig. 5) to prioritize requests for data to facilitate future multifactorial analysis. The distribution of prior probabilities for MLH1 and MSH2 class 3 variants was clearly bimodal, suggesting that ~50% of MLH1 and MSH2 missense variants may be classified as pathogenic after further investigation. In total, 401 missense variants had extreme prior probabilities of ≤20% or ≥80%, with 270 having probabilities of <10% or >90%, indicating that classification of a variant as class 1 or class 5 could be easily performed by incorporating segregation or tumor information. It is also possible that some class 3 variants with low prior probability of pathogenicity based on the predicted missense alteration would cause splicing aberrations, as already observed for 42 of the 746 not obviously truncating nonsynonymous variants. Incorporation of validated bioinformatic splicing prediction tools into the MMR gene multifactorial model, as is under development for BRCA1 and BRCA2 (ref. 35) , will assist in the prioritization of variants with the potential to disrupt splicing. In investigation of the potential effects of class 3 regulatory variants (Online Methods), all 15 5′ UTR variants fell within multiple transcription factor binding sites, but no evidence for interruption of microRNA binding was found for 6 variants in the 3′ UTR (data not shown). Multifactorial analyses and transcription assays would help elucidate whether these variants affect gene function.
Class 3 variants of uncertain relevance
DISCUSSION
The InSiGHT VIC has successfully undertaken a collaborative effort to establish standardized variant interpretation guidelines, encourage data submission and provide objective assessment of MMR gene variants involved in Lynch syndrome. The criteria developed provide a basis for the standardized clinical classification of variants to inform patient and family management through genetic counseling 10 . This initiative has achieved the systematic evaluation of 2,360 constitutional variants, which will benefit thousands of families internationally. Notably, 605 variants not resulting in the introduction of a premature termination codon, including 217 nonsynonymous substitutions, have now been assigned to class 5 (pathogenic) and class 4 (likely pathogenic) or to class 1 (not pathogenic) and class 2 (likely not pathogenic). The assigned classes of these variants can now also be used as standards for the calibration of functional assays 36, 37 .
The clinical relevance of 32% of the variants investigated remains uncertain. A large proportion of these (71%) were private variants occurring in only one family, and these variants are difficult to classify a n a ly s i s owing to the paucity of available clinical information. Clinicians have a fundamental role in promoting the collection of segregation information and other data relevant for classification. We anticipate that the development of this interpretation scheme, along with the implementation of microattribution, will incentivize assistance in the accumulation of clinical data. The value of microattribution for data accrual has previously been demonstrated for hemoglobinopathies 24 , and the InSiGHT initiative now demonstrates the clinical usefulness of data collection. The promotion of standardized data formats will assist in the transition to fully quantitative, unbiased classification, eventually incorporating other components of the qualitative guidelines. In addition, the difficulties experienced in interpreting apparently discordant data from functional assays emphasize the importance of assay validation and standardization 38, 39 . Such experience will be directly applicable to the functional analysis of deep intronic and regulatory variants, which are increasingly detected with the advancement of DNA sequencing technologies.
To accommodate the lower penetrance and reported lower degrees of tumor MSI associated with MSH6 and PMS2 mutations 28, 29, [40] [41] [42] [43] [44] , gene-specific criteria should also be considered for future iterations of the classification guidelines, for example, stipulating the inclusion of segregation odds for MSH6 and PMS2 variants for classification or using modified panels to detect MSI status.
Another challenging issue to contemplate will be incorporating alleles of intermediate risk 45 into classification schemes, including the clinical recommendations that might be linked to such variants. The identification of a subset of MMR gene alleles with apparently discordant clinical and functional features that renders them resistant to classification will provide the basis for future studies to define the most appropriate methodology and criteria to identify such variants. Further studies will also be required to assess whether variants resulting in abrogated DNA damage response but normal MMR 46 are associated with the same clinical features as classical pathogenic mutations in MMR genes.
The InSiGHT database is a well-recognized resource for the clinical and research communities, receiving over 20,000 hits per month. The development and adoption of standard templates allows transparency in the review process. Database users can view relevant information and sources in relation to information on guideline interpretation when considering the classification provided by the committee. The guidelines must evolve to accommodate additional kinds of evidence, but we anticipate no clinical issues as long as variant classifications are dated and linked to a dated set of guidelines with the supporting information used to derive classifications. Final classifications have also been submitted to the NCBI ClinVar database for higher exposure, but expert classifications and underlying data rest with InSiGHT.
To our knowledge, this is the first large-scale comprehensive classification effort demonstrating the value of evaluation by expert panel in the curation of an LSDB and providing summary information used to assign variant pathogenicity. This initiative also shows how classification may be assisted by promoting standardized data submission from stakeholders in the clinical and research settings, thereby allowing access to unpublished clinical and functional information used to facilitate variant classification. Thus, the InSiGHT initiative provides a key model of LSDB-centric multidisciplinary collaboration for the transparent interpretation of DNA variants. 
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